FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
tendered her resignation as Vice President of Corporate Accounting
and Controller of the Company, effective as of March 10, 2017.
separation agreement and general release (the Separation
Agreement), which sets forth the terms of Ms. Smith’s separation.
to the Separation Agreement, the effective date of Ms. Smiths
resignation has been changed to March 31, 2017 (the Termination
Date). Subject to Ms. Smith agreeing to a release of claims and
complying with certain other continuing obligations contained
therein, the Company shall continue to employ Ms. Smith through the
Termination Date at her current full rate of pay and pay Ms. Smith
the total amount of twenty-six thousand dollars ($26,000), less
applicable withholdings and deductions. In addition, the Company
will (a) pay any and all of Ms. Smith’s compensation due and owing
to her as of the Termination Date, including any accrued and unused
vacation for fiscal year 2016 and 2017, in accordance with the
Companys usual compensation and payroll practices, and (b)
reimburse Ms. Smith for all reasonable unreimbursed business
expenses incurred by her as of the Termination Date in accordance
with the Companys expense reimbursement policy.
purport to be complete, and is qualified in its entirety by
reference to such agreement, filed as Exhibit 10.1 and incorporated
herein by reference.
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
10.1
|
|
Separation Agreement and General Release, dated March 3,
2017, by and between Fibrocell Science, Inc. and Kimberly M. Smith |
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults. FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Recent Trading Information
FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) closed its last trading session down -0.024 at 0.658 with 146,185 shares trading hands.